Bold claim upfront: investing $1,000 in February could tap into a healthcare rebound as the market normalizes, turning undervalued stocks into meaningful gains. And this is where it gets controversial: a few missteps now could wipe out those gains just as quickly. Below is a rewritten, expanded version that preserves all key information while clarifying concepts for beginners and offering a balanced view.
The broader market mood has been gloomy across many sectors, with artificial intelligence largely standing apart as a bright spot. The health-insurance space, in particular, faced an unusually volatile year in 2025 due to a surprise surge in healthcare costs from multiple sources, which squeezed profits for insurers. That pressure has driven down stock prices across the sector.
Two notable names stand out for February: Oscar Health and UnitedHealth Group. Oscar Health, which aims to disrupt the individual health-insurance market through tech-enabled services and ACA marketplace offerings, has seen its stock retreat. UnitedHealth Group, a long-established health insurer, has also faced profitability headwinds but remains a heavyweight with substantial scale. The pullback across both stocks has created what some investors view as a persuasive entry point for 2026, assuming profits can rebound.
Why these two stocks appear attractive as part of a $1,000 February playbook:
Oscar Health: a challenger in health insurance
- Oscar Health began with the goal of simplifying the experience for individual payors, focusing on the ACA marketplace and leveraging technology to improve pricing, service, and retention. By delivering easier-to-use tools, competitive pricing, and better customer satisfaction, Oscar has been able to gain market share in the individual health-insurance segment.
- As of February this year, Oscar Health reported 3.4 million insured members, a notable increase from roughly 400,000 at the end of 2020. However, the stock has traded lower due to concerns about the potential expiration of subsidies for lower-income ACA enrollees after 2025 and uncertainties about how this will affect Oscar’s customer base in 2026. Additionally, rising healthcare costs in 2025 contributed to some profitability pressure for Oscar.
- Despite these headwinds, 2026 appears to present a path to recovery. The company has emphasized price adjustments and improved customer retention, guiding revenue to a potential range of $11.7 billion for 2025 up to as much as $19 billion for 2026, with operating earnings estimated between $250 million and $450 million. With a market capitalization around $3.6 billion, some investors view Oscar as an attractive speculative or growth-focused investment at current levels.
UnitedHealth Group (a legacy insurer): potential rebound candidate
- UnitedHealth faced several challenges in 2025, including the same general cost pressures affecting the industry, a cybersecurity incident, allegations of exaggerated health claims for Medicare beneficiaries, and an antitrust lawsuit. These factors contributed to earnings headwinds and a lower share price relative to prior highs.
- In 2026, UnitedHealth anticipates revenue of about $439 billion and operating earnings near $24 billion, supported by rate repricings for premiums and ongoing demand for private-healthcare services. The stock trades at roughly 10 times these operating earnings expectations, translating into a valuation that some investors consider compelling given the company’s scale and diversified business model.
- As the U.S. population ages and healthcare inflation remains a consideration, stable cash flow and a long history of earnings resilience could help UnitedHealth maintain steady growth over the next decade. That said, investors should be mindful of the risks tied to regulatory, pricing, and competitive dynamics in the sector.
Bottom line: with both stocks offering substantial headroom if 2026 profits materialize as expected, a $1,000 investment into February could potentially capture upside as the sector stabilizes. Oscar Health represents the high-growth, disruption-oriented option, while UnitedHealth provides exposure to a proven, large-scale insurer that could benefit from continued demand for private healthcare coverage.
Controversy note: some analysts warn that even with the recovery narrative, the healthcare-insurance space remains highly sensitive to government policy changes, subsidy timing, and cost-control outcomes. The question to ponder is whether subsidies will be extended or altered in ways that could materially affect Oscar’s subscriber growth or UnitedHealth’s pricing power. Do you think policy shifts will favor more subsidies and access, or will cost-containment measures dominate the landscape in 2026? Share your perspective in the comments.
